31 post-doctoral-position-in-nanomaterials scholarships at Amsterdam UMC in Netherlands
Sort by
Refine Your Search
-
staff position within a Research Infrastructure? No Offer Description Rheumatoid arthritis (RA) is a chronic disabling autoimmune disease with an unknown aetiology. The van Egmond and van Baarsen labs
-
staff position within a Research Infrastructure? No Offer Description In recent years it has become increasingly clear that dysfunctional glia (astrocytes and microglia) play a major role in the
-
staff position within a Research Infrastructure? No Offer Description Which biomarkers can predict disease progression in Alzheimer’s disease? Or which factors predict treatment response in acute stroke
-
staff position within a Research Infrastructure? No Offer Description Diffuse Large B cell Lymphoma (DLBCL) is the most common aggressive (fast-growing) Non-Hodgkin-lymphoma with heterogeneous clinical
-
staff position within a Research Infrastructure? No Offer Description The PhD student will work on gene therapy development for Gyrate atrophy of the choroid and retina (GACR), a rare genetic (neuro
-
staff position within a Research Infrastructure? No Offer Description Macrophages are key immune regulators in atherosclerosis. Their dysregulation leads to disease progression and associated clinical
-
staff position within a Research Infrastructure? No Offer Description Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS). Current treatment regimens effectively
-
) Type of Contract Permanent Job Status Not Applicable Hours Per Week 36.0 Is the job funded through the EU Research Framework Programme? Not funded by an EU programme Is the Job related to staff position
-
) Type of Contract Temporary Job Status Not Applicable Hours Per Week 36.0 Is the job funded through the EU Research Framework Programme? Not funded by an EU programme Is the Job related to staff position
-
staff position within a Research Infrastructure? No Offer Description Would you like to contribute to the optimization of drug treatment with tyrosine kinase inhibitors in primary and metastatic brain